Delivery Order SPE2DB24D2105-SPE2DB25FAQDA
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,797.51 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen injectors. This competitive award, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a firm fixed-price delivery order with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $64,305.29 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/mL pen injectors. This firm fixed-price delivery order, awarded September 5, 2025, with completion targeted for September 8, 2025, will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's capability to compete in open...
- The Defense Logistics Agency has awarded a delivery order valued at $40,155.43 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen injectors, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside transaction executed on September 2, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with extensive experience...
- The Defense Logistics Agency awarded a delivery order valued at $113,263.44 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of SKYRIZI 150 mg/mL pen injectors. This is a firm fixed price, competitively awarded contract with no set-aside designation, with performance to be completed by August 8, 2025, at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen injectors on June 2, 2025, with completion expected by June 3, 2025. This firm fixed-price delivery order represents a non-competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 2026. SKYRIZI is a biologic immunosuppressant used to...
- The Defense Logistics Agency awarded a $18,136.65 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen injectors, with an ultimate completion date of August 22, 2025. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a $38,911.60 delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of SKYRIZI 150 mg/ml pen injectors. This firm fixed price, non-set-aside contract will be completed by August 27, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a $28,786.07 firm fixed-price delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen injectors, with an ultimate completion date of July 15, 2025. This non-set-aside delivery order represents a competitive award to the pharmaceutical distributor, which is headquartered in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion prime vendor...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 ml on-body injector devices. This firm fixed price delivery order, issued on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a competitive award with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and falls under the company's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $64,242.74 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen injections. This firm fixed-price, competitively awarded delivery order was issued on June 17, 2025, with an ultimate completion date of June 18, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open competition among qualified...
- SPE2DB24D2105Indefinite Delivery Contract
- SPE2DB24D2105-SPE2DB25FAQDADelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $52,614.79 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/mL pen injectors. This firm fixed price delivery order, awarded on August 25, 2025, represents a non-set-aside competitive award with an ultimate completion date of August 26, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive global pharmaceutical support vehicle that extends through December 2026 and enables the company to supply a broad range of pharmaceuticals and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, has demonstrated significant capability as a federal medical supply vendor through its extensive contract portfolio with the DLA and Defense Health Agency. The company's federal procurement activities span multiple therapeutic domains, from specialty medications and brand-name drugs to vaccines and medical devices, consistently delivered through competitively awarded delivery orders with firm fixed pricing. This particular delivery order for SKYRIZI, a biologic treatment for immunodermatological conditions, exemplifies the company's role as a critical vendor supporting military and veteran healthcare systems through the DLA's pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $52.6k | 8/25/25 |